New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:51 EDTDRTXDurata Therapeutics price target raised to $18 from $14 at JMP Securities
JMP Securities increased its price target on Durata ahead of its evaluation of a single dose version of its dalbavancin anti-infection drug. The firm thinks that creating a single dose regimen for the drug will increase its market penetration beginning around 2017. JMP Securities reiterates an Outperform rating on the shares.
News For DRTX From The Last 14 Days
Check below for free stories on DRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for DRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use